Lilly Buying Verve for $1.3 Billion
- Posted by ISPE Boston
- On June 20, 2025
In one of the largest acquisitions locally this year, Eli Lilly is buying Verve Therapeutics in a deal worth $1.3 billion. Boston-based Verve is a clinical-stage company developing genetic medicines for cardiovascular disease. The transaction is expected to close in Q3. Verve’s lead programs – VERVE-102, VERVE-201, and VERVE-301 – target the three lipoprotein drivers […]
Read More